Nursing and Health Professions
Ranibizumab
100%
Vasculotropin
100%
Network Meta-Analysis
100%
Diabetic Macular Edema
100%
Confidence Interval
80%
Aflibercept
73%
Bevacizumab
60%
Laser
53%
Visual Acuity
53%
Drug
46%
Laser Coagulation
20%
Central Retinal Thickness
20%
Angiogenesis Inhibitor
20%
Adverse Event
13%
Death
13%
Visual Impairment
13%
Diabetic Retinopathy
13%
Thromboembolism
13%
Sham Procedure
13%
Antiangiogenic Therapy
13%
Standard
6%
Meta Analysis
6%
Data Base
6%
Quality of Life
6%
Control
6%
Analysis
6%
Follow up
6%
Cause of Death
6%
Variance
6%
Complication
6%
Best Corrected Visual Acuity
6%
Pegaptanib
6%
Health Care Quality
6%
Edema
6%
Low Level Laser Therapy
6%
Pharmacology, Toxicology and Pharmaceutical Science
Vasculotropin
100%
Ranibizumab
100%
Diabetic Macular Edema
100%
Aflibercept
73%
Bevacizumab
60%
Drug
46%
Randomized Controlled Trial
20%
Angiogenesis Inhibitor
20%
Adverse Event
13%
Placebo
13%
Death
13%
Visual Impairment
13%
Diabetic Retinopathy
13%
Thromboembolism
13%
Cause of Death
6%
Complication
6%
Antiangiogenic
6%
Pegaptanib
6%
Edema
6%
Antiangiogenic Therapy
6%